Ion Channel Drug Discovery - Therapeutic Opportunities & Technology Progress

Increased knowledge of novel targets in combination with a strong progress in drug discovery technologies has strongly contributed to the fast development in ion channel drug discovery that we are witnessing today. This progress is helping to pave the way for immense commercial opportunities. In this report, BioSeeker Group has identified and analyzed advancements in novel, ion-channel targeted drug development as well as technology breakthroughs.

During the last two years a vast amount of commercial data has been presented, which clearly implies that this is a field on the move. The report "Ion Channel Drug Discovery - Therapeutic Opportunities & Technology Progress" will provide you with the foundation needed to study this field further.

Ion channels play significant role in a great number of cell types and occur as large families of related genes with cell-specific expression patterns. Progress in transcription profiling is revealing the tissue specific distributions of ion channels. Further, many common diseases, such as cardiac arrhythmias, diabetes, hypertension, angina pectoris and epilepsy, have been related to dysfunction of ion channels. Considering this in combination with the access to the human genome, ion channels will most probably play a much more important role as therapeutic drug targets in the future.

One of the major difficulties faced by drug discovery companies has been to screen for compounds interacting with ion channels in an efficient manner. The last two years have resulted in important development of the current screening techniques, and as a result it is possible that we will witness a breakthrough for the ion channel drug discovery within a few years time.

BioSeeker Group has recognized the demand for a continuous surveillance within the field of ion channels as targets for drug discovery. We have also surveyed and investigated the development of new ion channel screening assays - an equally important and much requested aspect of ion channel drug discovery. This report analyzes the technical development of ion channel drug screening techniques such as ion- flux-, patch-clamping, patch-on-a-chip and high-throughput assays. Moreover, it will provide you with an in-depth review of the current targets and drugs in ion channel R&D in both pre-clinical and clinical developmental stage. The report will also provide you with information about key alliances behind the progress.

The report consists of +180 pages (+35 000 words), including +50 companies with corporate descriptions. To assist you in grasping the material in the report we have generated various illustrative tables and figures.

Complementary Database

As a customer of this report you have the opportunity to purchase our complementary patent database at a significantly discounted price. This database presents several hundred important patents related to ion channel drug discovery, improving your capability for further in-house analyses of the field. The database is easy to use, yet includes advanced search functionality. Price: $950 US. Contact us at bioinfo@bioseeker.com for further information.

Companies Included in the Report:

Abbott Laboratories, Able Laboratories, Agis Industries Ltd., Akorn, Inc., ALA Scientific Instruments Inc., American Pharmaceutical Partners, Andrx Corporation, Apotex Inc., AstraZeneca, Athena Neurosciences, Aurora Biosciences, Aurora Biomed Inc., Aventis Pharmaceuticals Inc., AVIVA Biosciences Corporation Inc., Axon Instruments, Barr Laboratories, Bayer, BioChip, Biofocus, Bioniche Life Sciences Inc., Biovail, Bradley Pharmaceuticals, Cardiome Pharma Corp, Cellectricon, Celltech Group PLC., Central Research Laboratories Limited (CRL), ChanTest, CeNeS Pharmaceuticals Inc., Cortex, Dentsply International Inc., Cytocentrics, Cytoplex Biosciences, Devgen, Elan Corporation PLC, Eli Lilly and Company, Endo Pharmaceuticals Holdings Inc., Fougera, Flyion, GlaxoSmithKline, IMPAX Laboratories Inc., IOMED, Johnson & Johnson, KV Pharmaceutical Company, Lannett Company Inc., Mayne Pharma USA Inc., Merck KGaA, Molecular Devices, Morton Grove Pharmaceuticals Inc., Mylan Laboratories Inc., Nanion Technologies, Neurion Pharmaceuticals Inc, Neurosearch, NexMed, Nissan Chemical Industries Ltd., Novartis Pharmaceuticals Corporation, Orion Pharma, Oryx Pharmaceuticals Inc., Parke-Davis, Pfizer Inc., Ranbaxy Laboratories, Scion Pharmaceutical, Sanofi-Synthelabo, Sophion Bioscience Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Vernalis plc., Wyeth and Xcel Pharmaceuticals.